147 related articles for article (PubMed ID: 31258898)
1. Indoleamine 2,3-dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells.
Sounidaki M; Pissas G; Eleftheriadis T; Antoniadi G; Golfinopoulos S; Liakopoulos V; Stefanidis I
Biomed Rep; 2019 Jun; 1(1):1-5. PubMed ID: 31258898
[TBL] [Abstract][Full Text] [Related]
2. Uric acid increases cellular and humoral alloimmunity in primary human peripheral blood mononuclear cells.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Nephrology (Carlton); 2018 Jul; 23(7):610-615. PubMed ID: 28477373
[TBL] [Abstract][Full Text] [Related]
3. In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2017 Sep; 49(9):1691-1697. PubMed ID: 28508247
[TBL] [Abstract][Full Text] [Related]
4. A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity.
Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
Int Immunopharmacol; 2017 Sep; 50():48-54. PubMed ID: 28628770
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells.
Eleftheriadis T; Pissas G; Sounidaki M; Tsogka K; Antoniadis N; Antoniadi G; Liakopoulos V; Stefanidis I
Int J Mol Med; 2016 Nov; 38(5):1605-1613. PubMed ID: 27667153
[TBL] [Abstract][Full Text] [Related]
6. Human regulatory macrophages are potent in suppression of the xenoimmune response via indoleamine-2,3-dioxygenase-involved mechanism(s).
Guo F; Hu M; Huang D; Zhao Y; Heng B; Guillemin G; Lim CK; Hawthorne WJ; Yi S
Xenotransplantation; 2017 Sep; 24(5):. PubMed ID: 28771838
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation.
Eleftheriadis T; Pissas G; Antoniadi G; Spanoulis A; Liakopoulos V; Stefanidis I
Int Immunol; 2014 Dec; 26(12):673-84. PubMed ID: 25064493
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of the aerobic glycolysis inhibitor dichloroacetate and of the Krebs cycle inhibitor LW6 on cellular and humoral alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Liakopoulos V; Stefanidis I
Biomed Rep; 2017 Nov; 7(5):439-444. PubMed ID: 29181155
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.
Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
Immunology; 2015 Oct; 146(2):292-300. PubMed ID: 26147366
[TBL] [Abstract][Full Text] [Related]
10. IDO decreases glycolysis and glutaminolysis by activating GCN2K, while it increases fatty acid oxidation by activating AhR, thus preserving CD4+ T‑cell survival and proliferation.
Eleftheriadis T; Pissas G; Liakopoulos V; Stefanidis I
Int J Mol Med; 2018 Jul; 42(1):557-568. PubMed ID: 29693118
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation.
Brandacher G; Margreiter R; Fuchs D
Curr Opin Organ Transplant; 2008 Feb; 13(1):10-5. PubMed ID: 18660700
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells.
Eleftheriadis T; Pissas G; Yiannaki E; Markala D; Arampatzis S; Antoniadi G; Liakopoulos V; Stefanidis I
Hum Immunol; 2013 Dec; 74(12):1501-9. PubMed ID: 23993986
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2, 3-dioxygenase Up-regulates Hypoxia-inducible Factor-1α Expression by Degrading L-tryptophan but Not Its Activity in Human Alloreactive T-cells.
Eleftheriadis T; Pissas G; Liakopoulos V; Stefanidis I
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):56-67. PubMed ID: 29512370
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Humoral Alloimmunity in Mixed Lymphocyte Reaction.
Pissas G; Eleftheriadis T
Bio Protoc; 2019 Jan; 9(2):e3139. PubMed ID: 33654885
[TBL] [Abstract][Full Text] [Related]
15. [EFFECTS OF INDOLEAMINE 2, 3-DIOXYGENASE GENE MODIFIED BONE MARROW MESENCHYMAL STEM CELLS IN RAT COMPOSITE TISSUE ALLOGRAFT REJECTION].
Han F; Wang Y; Wang Y; Jia Y; Yang L; Jia W; Fang X; Bai X; Hu D
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2014 Jun; 28(6):745-51. PubMed ID: 26455230
[TBL] [Abstract][Full Text] [Related]
16. The role of tryptophan catabolism in acquisition and effector function of memory T cells.
Dai H; Dai Z
Curr Opin Organ Transplant; 2008 Feb; 13(1):31-5. PubMed ID: 18660704
[TBL] [Abstract][Full Text] [Related]
17. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase.
Swanson KA; Zheng Y; Heidler KM; Mizobuchi T; Wilkes DS
Am J Respir Cell Mol Biol; 2004 Mar; 30(3):311-8. PubMed ID: 12959949
[TBL] [Abstract][Full Text] [Related]
18. The indoleamine 2,3-dioxygenase inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic glycolysis and decreases interleukin-10 production in human lymphocytes.
Eleftheriadis T; Pissas G; Karioti A; Antoniadi G; Liakopoulos V; Dafopoulou K; Pournaras S; Koukoulis G; Stefanidis I
Immunol Invest; 2012; 41(5):507-20. PubMed ID: 22594922
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells transfected with indoleamine 2,3-dioxygenase gene suppressed acute rejection of cardiac allograft.
Li C; Liu T; Zhao N; Zhu L; Wang P; Dai X
Int Immunopharmacol; 2016 Jul; 36():31-38. PubMed ID: 27107370
[TBL] [Abstract][Full Text] [Related]
20. The tryptophan derivative, tranilast, and conditioned medium with indoleamine 2,3-dioxygenase-expressing cells inhibit the proliferation of lymphoid malignancies.
Suwa S; Kasubata A; Kato M; Iida M; Watanabe K; Miura O; Fukuda T
Int J Oncol; 2015 Mar; 46(3):1369-76. PubMed ID: 25572287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
